Thea E. Hetland Falkenthal started at the Cancer Registry in 2022, where she works as a researcher at the section for molecular epidemiology and infections. Thea received her medical degree from Aarhus University in Denmark, she is a specialist in oncology and obtained her PhD in 2013 when she defended her thesis on the subject of ovarian cancer. She works with a number of projects related to the prevention of cervical cancer, especially related to HPV vaccination. She leads the project "LTFU: Long-term follow-up of women who took part in a vaccine against cervical cancer", where the duration, safety and protective effect of two different HPV vaccines are investigated.
Thea Falkenthal received her MD from the University of Aarhus in Denmark in 2006 and is a specialist in clinical oncology. In 2013, she finished her PhD on ovarian cancer. From 2008 to 2022, Thea worked as a clinician at Oslo University Hospital, the Norwegian Radiumhospital, where she primarily treated women who had different types of gynecological cancers. With a particular focus on the treatment of cervical cancer, she served as attending physician at the "Section for Gynecological Radiation Therapy" in the last years before joining the Cancer Registry in 2022.
Thea Falkenthal is a researcher at the Section for Molecular Epidemiology and Infections and works with issues related to HPV vaccination and prevention of cervical cancer. She is the Principal Investigator of LTFU: Long-term follow-up of women who participated in studies with vaccines against cervical cancer, where the duration, safety, and protective effect of various HPV vaccines are investigated.
LTFU: Langtidsoppfølging av kvinner som deltok i vaksine mot livmorhalskreft
Livmorhalskreft hos eldre kvinner
Prognostiske faktorer ved peniskreft - samarbeidsprosjekt med Haukeland Univ.sykehus
Publications:
Moen CA, Falkenthal TE, Thorkelsen TK, Hopland A, Rio OE, Honoré A, Juliebø-Jones P, Dongre HN, Costea DE, Bostad L, Brennan P, Johansson M, Ferreiro-Iglesias A, Brenner N, Waterboer T, Nygård M, Beisland C. Penile Cancers Attributed to Human Papillomavirus Are Associated with Improved Survival for Node-positive Patients. Findings from a Norwegian Cohort Study Spanning 50 Years. Eur Urol Oncol. 2023 Nov 8:S2588-9311(23)00233-X. doi: 10.1016/j.euo.2023.10.013. Epub ahead of print. PMID: 37949729.
Onallah H, Catane LJ, Tropé CG, Hetland Falkenthal TE, Reich R, Davidson B. Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma. Virchows Arch. 2018 Oct;473(4):463-470. doi: 10.1007/s00428-018-2418-x. Epub 2018 Jul 21. PMID: 30032361.
Davidson B, Bjørnerem M, Holth A, Hellesylt E, Hetland Falkenthal TE, Flørenes VA. Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma. Gynecol Oncol. 2018 Jul;150(1):136-142. doi: 10.1016/j.ygyno.2018.05.007. Epub 2018 May 24. PMID: 29804637.
Davidson B, Holth A, Wang Z, Hellsylt E, Tropé CG, Hetland Falkenthal TE, Holm R. Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma. APMIS. 2018 Apr;126(4):309-313. doi: 10.1111/apm.12816. Epub 2018 Feb 21. PMID: 29464778.
Filippov-Levy N, Cohen-Schussheim H, Tropé CG, Hetland Falkenthal TE, Smith Y, Davidson B, Reich R. Expression and clinical role of long non-coding RNA in high-grade serous carcinoma. Gynecol Oncol. 2018 Mar;148(3):559-566. doi: 10.1016/j.ygyno.2018.01.004. Epub 2018 Jan 5. PMID: 29310950.
Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. Hum Pathol. 2016 Aug;54:74-81. doi: 10.1016/j.humpath.2016.03.010. Epub 2016 Apr 8. PMID: 27063471.
Nymoen DA, Hetland Falkenthal TE, Holth A, Ow GS, Ivshina AV, Tropé CG, Kuznetsov VA, Staff AC, Davidson B. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma. Gynecol Oncol. 2015 Oct;139(1):30-9. doi: 10.1016/j.ygyno.2015.07.107. Epub 2015 Jul 29. PMID: 26232338.
Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. Mol Cancer. 2015 Feb 18;14:44. doi: 10.1186/s12943-015-0317-1. PMID: 25889687; PMCID: PMC4336750.
Media:
Skal vi screene og konisere inn i evigheten eller bytte hpv-vaksine? - Dagens medisin 2023
White paper: Raskere eliminering av HPV og livmorhalskreft - Kreftregisteret.no 2023
HPV-vaksinen i voksen alder: -Alle har nytte av vaksinen - Norsk Helseinformatikk 2023
HPV-vaksinen må bli invitert til voksenfesten - Aftenposten 2023
Jo, vi kan utrydde HPV og livmorhalskreft raskere - Aftenposten 2023
Vaksinering og screening mot HPV-virus - Dagens medisin 2023
Kan utrydde livmorhalskreft - Altså 2023
Hvor fort vi eliminerer livmorhalskreft i Norge, er et valg - Altså 2023
Conferences:
Long-term effectiveness and immunogenicity of the 9-valent human papilloma virus (9VHPV) vaccine in Scandinavian countries - EUROGIN 2023
Long-term effectiveness and immunogenicity of the 9-valent human papilloma virus (9VHPV) vaccine in Scandinavian countries - IPVC 2023
